Humacyte (HUMA) Operating Income (2020 - 2026)
Humacyte (HUMA) reported Operating Income of -$28.9 million for Q1 2026, down 24.72% year-over-year from -$38.4 million in Q1 2025, and up 6.16% quarter-over-quarter from -$30.8 million in Q4 2025.
Humacyte (HUMA) Operating Income (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Operating Income data on file, last reported at -$28.9 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$28.9 million, down 24.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$113.9 million (down 2.57% YoY), and the FY2025 annual result was -$108.1 million, up 5.47% from the prior year.
- Operating Income improved to -$28.9 million in Q1 2026 per HUMA's latest filing, from -$30.8 million in the prior quarter.
- Over five years, Operating Income peaked at -$18.5 million in Q2 2022 and troughed at -$30.8 million in Q4 2025.
- A 5-year average of -$25.7 million and a median of -$26.2 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2025: Operating Income slumped 44.25% in 2023, then climbed 19.33% in 2025.
- A 5-year view of Operating Income shows it stood at -$20.8 million in 2022, then retreated by 25.8% to -$26.2 million in 2023, then decreased by 7.33% to -$28.1 million in 2024, then decreased by 9.74% to -$30.8 million in 2025, then gained by 6.16% to -$28.9 million in 2026.
- Business Quant data shows HUMA's Operating Income at -$28.9 million in Q1 2026, -$30.8 million in Q4 2025, and -$24.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -65.83 Mn |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | -28.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.94 Mn |
| Dec 31, 2025 | -30.84 Mn |
| Sep 30, 2025 | -24.39 Mn |
| Jun 30, 2025 | -29.73 Mn |
| Mar 31, 2025 | -23.20 Mn |
| Dec 31, 2024 | -28.10 Mn |
| Sep 30, 2024 | -30.23 Mn |
| Jun 30, 2024 | -29.50 Mn |
| Mar 31, 2024 | -26.58 Mn |
| Dec 31, 2023 | -26.18 Mn |
| Sep 30, 2023 | -24.62 Mn |
| Jun 30, 2023 | -26.73 Mn |
| Mar 31, 2023 | -22.51 Mn |
| Dec 31, 2022 | -20.81 Mn |
| Sep 30, 2022 | -23.49 Mn |
| Jun 30, 2022 | -18.53 Mn |
| Mar 31, 2022 | -21.76 Mn |
| Dec 31, 2021 | -21.63 Mn |
| Sep 30, 2021 | -20.54 Mn |
| Jun 30, 2021 | -19.27 Mn |